Subanalyses of data from the LIBERTY PN-PRIME and LIBERTY PN-PRIME2 studies illustrate how dupilumab for prurigo nodularis can better patient outcomes, including quality of life and symptom burden.
Currently, the tumor necrosis factor inhibitor adalimumab is the only biologic therapy approved for the treatment of moderate to severe hidradenitis suppurativa.